Rimantadine Kids, 2 mg/ml syrup 100 ml

Rimantadine is an antiviral agent derived from adamantane; it is active against various strains of influenza A virus. Being a weak base, rimantadine acts by increasing the pH of endosomes, the membrane-containing vacuoles that surround viral particles after they enter the cell. Preventing acidification in these vacuoles blocks the fusion of the viral envelope with the endosome membrane, thus preventing the transfer of viral genetic material into the cell cytoplasm. Rimantadine also inhibits the exit of viral particles from the cell, i.e. it interrupts the transcription of the viral genome.

Indications

Prevention and early treatment of influenza A in children over 1 year of age.

Rimantadine prophylaxis may be effective in contacts with people who are ill at home, in the spread of infection in isolated communities, and when there is a high risk of illness during an influenza epidemic.

Active ingredient

Composition

Active ingredient:

rimantadine hydrochloride – 2.0 mg.

Excipients:

sorbitol (sorbitol liquid) – 514.3 mg,

maltitol (maltitol liquid) – 514.3 mg,

sodium carmellose – 3.64 mg,

methyl parahydroxybenzoate – 1.15 mg,

strawberry flavoring – 0.63 mg,

purified water – up to 1 ml.

Interaction

Pharmacodynamic: rimantadine reduces the effectiveness of antiepileptic drugs.

Pharmacokinetic: adsorbents, astringents and envelopes reduce absorption of rimantadine.

The urine acidifying agents (acetazolamide, sodium bicarbonate, etc.) increase the concentration of rimantadine.

Paracetamol and ascorbic acid reduce the maximum concentration of rimantadine in plasma by 11%.

Cimetidine decreases clearance of rimantadine by 18 %.

The sorbitol contained in the drug may affect the bioavailability of simultaneously used drugs.

Because of the increased risk of dyspepsia, concomitant use with other medicinal products containing sorbitol is not recommended.

Directions for use

Therapeutic regimen:

It is taken orally (after meals), drinking water, according to the following scheme: children from 1 to 3 years – on the first day 10 ml (2 teaspoons) syrup (20 mg) 3 times a day (daily dose – 60 mg); 2 and 3 days – 10 ml 2 times a day (daily dose – 40 mg), 4 day – 5 day – 10 ml 1 time a day (daily dose – 20 mg).

Children from 3 to 7 years – on the first day – 15 ml (3 teaspoons) of syrup (30 mg) j times a day (daily dose – 90 mg); days 2 and 3 – 3 teaspoons 2 times a day (daily dose – 60 mg), day 4 – day 5 – 3 teaspoons once a day (daily dose – 30 mg).

Children from 7 to 10 years old take 25 ml (5 teaspoons) of syrup (50 mg) 2 times a day for 5 days (daily dose-100 mg).

Children 11 to 14 years old take 25 ml (5 teaspoons) of syrup (50 mg) 3 times a day for 5 days (daily dose – 150 mg).

The prophylactic regimen:

For prophylaxis, use:

For children from 1 to 3 years – 10 ml (2 teaspoons) of syrup (20 mg) once a day,

Children from 3 to 7 years old – 15 ml (3 teaspoons) of syrup (30 mg) once a day,

children over 7 years old – 25 ml (5 teaspoons) of syrup (50 mg) once a day for 10-15 days.

Please note! The daily dose of rimantadine should not exceed 5 mg per kg of body weight.

Special Instructions

The use of rimantadine for 2-3 days before and 6-7 hours after the appearance of clinical manifestations of influenza type A reduces the severity of disease symptoms and the degree of serological reaction. Some therapeutic effect may also occur if rimantadine is prescribed within 18 hours after the onset of the first flu symptoms.

An exacerbation of chronic comorbidities is possible with use.

In patients with epilepsy during the use of rimantadine the risk of an epileptic seizure increases. 15 ml of the syrup is equal to 1 bread unit (BE), which must be taken into account when administering the drug to patients with diabetes mellitus.

The appearance of viruses resistant to the drug is possible.

Sorbitol may cause abdominal discomfort and have a laxative effect. If these effects occur during treatment, discontinue the drug and see a physician.

Because of the increased risk of dyspeptic phenomena, concomitant use with foods containing significant amounts of sorbitol (prunes, etc.) is not recommended.

Impact on the ability to drive and operate vehicles

With regard to the likelihood of side effects on the central nervous system, caution should be exercised when driving vehicles and operating machinery.

Contraindications

Side effects

Cardiovascular system disorders: tachycardia, heart failure,

heart block, palpitations, arterial hypertension, impaired cerebral circulation, loss of consciousness.

Nervous system disorders: insomnia, dizziness, headache, irritability, fatigue, concentration disorders, motor disorders, drowsiness, depressed mood, euphoria, hyperkinesia, tremor, hallucinations, confusion, seizures.

Sensory organs: tinnitus, change or loss of sense of smell.

Respiratory system: shortness of breath, bronchospasm, cough.

Gastrointestinal tract: nausea, vomiting, loss of appetite, dry oral mucosa, abdominal pain, diarrhea, dyspepsia.

The skin and subcutaneous tissue: rash.

Others: fatigue.

Overdose

In some cases, if the recommended dose is exceeded, tearfulness and pain in the eyes, rapid urination, fever, constipation, sweating, inflammation of the oral mucosa, dry skin may occur.

Treatment: gastric lavage, symptomatic therapy: measures to maintain vital functions. Rimantadine is partially excreted by hemodialysis.

Pregnancy use

Similarities